Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Clinical trial NCT04869475 · UNKNOWN

Trial details

NCT number: NCT04869475
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Solid Tumors

Start date: 2021-04-20
Primary completion: 2022-04-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.